

Urgent Field Safety Notice

SBN-RPD-2015-006

RPD / Clinchem fully automated
Version 2
11-Mar-2015

Homocysteine under-recovery in EDTA samples

Product Name	HCYS
Product Description	Homocysteine enzymatic assay
Impacted Products / Part No	05385415190 HCYS (cobas c, COBAS INTEGRA®) 06542921190 HCYS (cobas c 701, 702) 05385377190 HCYS (MODULAR <P>)
Production Identifier (Lot No./Serial No.)	05385415190 Lot No.: 69781101 06542921190 Lot No.: 69781401 05385377190 Lot No.: 69780301
Type of Action	Field Safety Corrective Action (FSCA)

Dear Valued Customer,

Description of Situation

Customers complained about a 20% decrease in control levels when using non-Roche controls (e.g. ThermoFisher LiqImmune) with Homocysteine reagent lot 697811 on **cobas c** 501. After changing to lot 604303, the controls were within range. The comparison of patient samples with reagent lot 697811 vs 604303 showed a bias of up to 54%. EDTA plasma samples were used. This negative bias could, in the worst case, lead to inaccurately low Homocysteine results. However, it is unlikely that inaccurately low Homocysteine results would lead to an immediate adverse event, since it has been demonstrated that Homocysteine is a predictor of *long-term* (late cardiac events), rather than short-term cardiovascular risk.

Insufficiency of Mg^{2+} in R1 and R2 was identified as the root cause. Since $MgCl_2$ is hygroscopic, the content of the container was absorbing water. Consequently, an insufficient amount of Mg^{2+} was added to the reagents despite the correct weight of $MgCl_2$ salt. Mg^{2+} is necessary for enzyme activity, reagent stability and the practicability of EDTA plasma as sample type. At the time of lot release, the amount of Mg^{2+} added to the reagent was within specification for serum and EDTA samples. As the reagent neared the end of its shelf life, the sample bias became evident with EDTA samples where Mg^{2+} in the reagent was more easily chelated from the enzymes.

Homocysteine under-recovery in EDTA samples

Actions taken by Roche Diagnostics

- Root cause was already identified
- Corrective and Preventive Action has been initiated
- Overall good performance for all forthcoming lots is ensured until the end of shelf life

Actions to be taken by the customer/user

- Customers must stop using the affected product, discard it locally and switch to unaffected subsequent lots (see table below) of **HCYS**:

Analyzer module	Material No.	Affected lots	Exp. Date	Subsequent lots	Exp. Date
Modular <P>	05385377190	69780301	30 Apr 2015	60716101	31 Jan 2016
cobas c 501 cobas c 502 cobas c 311 COBAS INTEGRA 400 plus COBAS INTEGRA 800	05385415190	69781101	30 Apr 2015	60716801	31 Jan 2016
cobas c 701 cobas c 702	06542921190	69781401	30 Apr 2015	60717101	31 Jan 2016

Communication of this Field Safety Notice

Please transfer this notice to other organizations/individuals on which this action has an impact.

Please maintain awareness of this notice and resulting action for an appropriate period to ensure the effectiveness of the corrective action.

We sincerely apologize for any inconvenience caused by this issue and hope for your understanding and support.

Sincerely,

Roche Diagnostics Asia Pacific Pte Ltd

Email: sg.regulatory@roche.com

Homocysteine under-recovery in EDTA samples

ACKNOWLEDGMENT RECEIPT

This is to acknowledge the receipt of Roche Safety Board Advisory Notice: Homocysteine under-recovery in EDTA samples, dated 11-Mar-2015, regarding decrease in control levels when using non-Roche controls (e.g. ThermoFisher LiqImmune) with Homocysteine reagent lot 697811 on cobas c 501.

Received by:

Name & Signature

Hospital & Stamp

Date